CD274 and neoplasm: Finally, while the predictive value of PD-L1 has been demonstrated in several tumor types, this has not been the case in CRC in either the CHECKMATE-142 trial with nivolumab plus ipilimumab, or the phase I trial with pembrolizumab (5, 12).